318 related articles for article (PubMed ID: 30181258)
1. Diclofenac use and cardiovascular risks: series of nationwide cohort studies.
Schmidt M; Sørensen HT; Pedersen L
BMJ; 2018 Sep; 362():k3426. PubMed ID: 30181258
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.
Ray WA; Varas-Lorenzo C; Chung CP; Castellsague J; Murray KT; Stein CM; Daugherty JR; Arbogast PG; García-Rodríguez LA
Circ Cardiovasc Qual Outcomes; 2009 May; 2(3):155-63. PubMed ID: 20031832
[TBL] [Abstract][Full Text] [Related]
3. High- vs. low-dose diclofenac and cardiovascular risks: a target trial emulation.
Schmidt M; Arendt-Nielsen L; Hauge EM; Sørensen HT; Pedersen L
Eur Heart J Cardiovasc Pharmacother; 2023 Jul; 9(5):453-461. PubMed ID: 36921986
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials.
Schmidt M; Sørensen HT; Pedersen L
Drug Saf; 2022 Sep; 45(9):983-994. PubMed ID: 35909207
[TBL] [Abstract][Full Text] [Related]
5. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
Prescrire Int; 2016 Jan; 25(167):14-6. PubMed ID: 26942254
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Farkouh ME; Greenberg JD; Jeger RV; Ramanathan K; Verheugt FW; Chesebro JH; Kirshner H; Hochman JS; Lay CL; Ruland S; Mellein B; Matchaba PT; Fuster V; Abramson SB
Ann Rheum Dis; 2007 Jun; 66(6):764-70. PubMed ID: 17412741
[TBL] [Abstract][Full Text] [Related]
7. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Matchaba P; Gimona A; Hawkey CJ;
Lancet; 2004 Aug 21-27; 364(9435):665-74. PubMed ID: 15325831
[TBL] [Abstract][Full Text] [Related]
8. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
; Bhala N; Emberson J; Merhi A; Abramson S; Arber N; Baron JA; Bombardier C; Cannon C; Farkouh ME; FitzGerald GA; Goss P; Halls H; Hawk E; Hawkey C; Hennekens C; Hochberg M; Holland LE; Kearney PM; Laine L; Lanas A; Lance P; Laupacis A; Oates J; Patrono C; Schnitzer TJ; Solomon S; Tugwell P; Wilson K; Wittes J; Baigent C
Lancet; 2013 Aug; 382(9894):769-79. PubMed ID: 23726390
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study.
Schmidt M; Hallas J; Ernst MT; Pottegård A
Eur Heart J Cardiovasc Pharmacother; 2023 Sep; 9(6):562-569. PubMed ID: 37385823
[TBL] [Abstract][Full Text] [Related]
11. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
13. Prescriber responsibility, predictors for initiation, and 20-year trends in use of non-aspirin non-steroidal anti-inflammatory drugs in patients with cardiovascular contraindications: a nationwide cohort study.
Schmidt M; Pottegård A
Eur Heart J Cardiovasc Pharmacother; 2021 Nov; 7(6):496-506. PubMed ID: 32584988
[TBL] [Abstract][Full Text] [Related]
14. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study.
Schjerning Olsen AM; Fosbøl EL; Lindhardsen J; Folke F; Charlot M; Selmer C; Lamberts M; Bjerring Olesen J; Køber L; Hansen PR; Torp-Pedersen C; Gislason GH
Circulation; 2011 May; 123(20):2226-35. PubMed ID: 21555710
[TBL] [Abstract][Full Text] [Related]
15. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
Farkouh ME; Kirshner H; Harrington RA; Ruland S; Verheugt FW; Schnitzer TJ; Burmester GR; Mysler E; Hochberg MC; Doherty M; Ehrsam E; Gitton X; Krammer G; Mellein B; Gimona A; Matchaba P; Hawkey CJ; Chesebro JH;
Lancet; 2004 Aug 21-27; 364(9435):675-84. PubMed ID: 15325832
[TBL] [Abstract][Full Text] [Related]
17. Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy-A nationwide study in patients with osteoarthritis.
Barcella CA; Lamberts M; McGettigan P; Fosbøl EL; Lindhardsen J; Torp-Pedersen C; Gislason GH; Olsen AS
Basic Clin Pharmacol Toxicol; 2019 May; 124(5):629-641. PubMed ID: 30484960
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular safety of using non-steroidal anti-inflammatory drugs for gout: a Danish nationwide case-crossover study.
Bech-Drewes A; Bonnesen K; Hauge EM; Schmidt M
Rheumatol Int; 2024 Jun; 44(6):1061-1069. PubMed ID: 38581450
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
McGettigan P; Henry D
JAMA; 2006 Oct; 296(13):1633-44. PubMed ID: 16968831
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.
Nissen SE; Yeomans ND; Solomon DH; Lüscher TF; Libby P; Husni ME; Graham DY; Borer JS; Wisniewski LM; Wolski KE; Wang Q; Menon V; Ruschitzka F; Gaffney M; Beckerman B; Berger MF; Bao W; Lincoff AM;
N Engl J Med; 2016 Dec; 375(26):2519-29. PubMed ID: 27959716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
